Comparing Adherence to and Persistence with Antipsychotic Therapy Among Patients with Bipolar Disorder

Medication nonadherence is a significant problem among patients with bipolar disorder. To compare adherence and persistence among patients with bipolar disorder initiated on antipsychotics in a state Medicaid system over a 12 month follow-up period. Claims data for patients with bipolar disorder fro...

Full description

Saved in:
Bibliographic Details
Published in:The Annals of pharmacotherapy 2007-11, Vol.41 (11), p.1812-1818
Main Authors: Hassan, Mariam, Madhavan, S Suresh, Kalsekar, Iftekhar D, Makela, Eugene H, Rajagopalan, Kitty, Islam, Syed, Kavookjian, Jan, Miller, Lesley-Ann
Format: Article
Language:English
Subjects:
Adolescent
Adult
Adult and adolescent clinical studies
Analysis of Variance
Antipsychotic Agents - therapeutic use
Benzodiazepines - therapeutic use
Biological and medical sciences
Bipolar Disorder - drug therapy
Bipolar disorders
Databases, Factual
Dibenzothiazepines - therapeutic use
Female
Follow-Up Studies
Haloperidol - therapeutic use
Humans
Male
Medicaid
Medical sciences
Middle Aged
Mood disorders
Patient Compliance
Pharmacology. Drug treatments
Phenothiazines - therapeutic use
Proportional Hazards Models
Psychology. Psychoanalysis. Psychiatry
Psychopathology. Psychiatry
Quetiapine Fumarate
Retrospective Studies
Risperidone - therapeutic use
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Medication nonadherence is a significant problem among patients with bipolar disorder. To compare adherence and persistence among patients with bipolar disorder initiated on antipsychotics in a state Medicaid system over a 12 month follow-up period. Claims data for patients with bipolar disorder from a de-identified Medicaid database were examined. Patients were classified into 4 monotherapy treatment groups (risperidone, olanzapine, quetiapine, or typical antipsychotic) based on the first prescription filled between January 1, 1999, and December 31, 2001. Adherence and persistence were analyzed over a 12 month follow-up period. Adherence was measured using the Medication Possession Ratio (MPR). Persistence was defined as the total number of days from the initiation of treatment to therapy modification (ie, discontinuation, switching, or combination with another antipsychotic). Adjustment for confounding variables was undertaken using ordinary least-squares and Cox proportional hazard regression modeling. The mean MPRs were 0.68 for risperidone (n = 231), 0.68 for olanzapine (n = 283), 0.71 for quetiapine (n = 106), and 0.46 for typical antipsychotics (n = 205). Patients initiated on typical antipsychotics were 23.6% less adherent than patients initiated on risperidone (p < 0.001). Mean persistence (days) was 194.8 for risperidone, 200.9 for olanzapine, 219.8 for quetiapine, and 179.2 for typical antipsychotics. Extended Cox regression modeling indicated no significant differences between antipsychotics in hazards of therapy modification within 250 days of initiation. However, patients initiated on typical antipsychotics were 5.2 times more likely to modify therapy compared with those initiated on risperidone after 250 days of antipsychotic therapy (p < 0.001). Adherence and persistence were similar between atypical antipsychotic groups. The typical antipsychotic group, however, demonstrated lower adherence and a greater likelihood of patients modifying therapy compared with the risperidone cohort.
ISSN:1060-0280
1542-6270
DOI:10.1345/aph.1K205